AstraZeneca’s ‘Miracle Pill’ Returns
May 19th, 2009
When AstraZeneca got U.S. clearance to sell the lung cancer-fighting pill Iressa in May 2003, it seemed to be a victory for patients and the company. Chief Executive Tom McKillop predicted the pill would become a “megabrand” with sales of more than $1 billion.
“It is already clear that Iressa is a valuable product for many patients with lung cancer,” McKillop told Wall Street analysts, “but its full potential will only be evident when we see the results from the ongoing clinical studies.”